Halozyme Therapeutics Inc. (RV7)
FSX
92.84
+0.44 (+0.48%)
Closed
Aug 25, 2026
Day's Range
92.8492.84
52 wk Range
52.5093.36
Financial Statements - RV7 - Halozyme Therapeutics Inc.
Revenue
1.39B▲ 62.3%
Net Income
316.88M▼ 15.8%Net Margin 22.7%
EBITDA
890.64M▲ 66.1%
Free Cash Flow
356.81M▼ 10.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 1.39B | 860.30M | 829.25M | 660.11M | 443.31M | 267.59M |
| Cost of Goods | 228.77M | 135.07M | 192.36M | 139.30M | 81.41M | 43.36M |
| Gross Profit | 1.16B | 725.22M | 636.89M | 520.81M | 361.89M | 224.22M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 802.59M | 467.27M | 337.57M | 267.53M | 275.90M | 144.25M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -317.59M | 20.12M | 29.51M | -1.66M | -19.85M | 5.42M |
| Pre Tax Income | 466.87M | 472.06M | 348.32M | 248.91M | 248.51M | 129.30M |
| Income Tax | 149.98M | 95.78M | 66.73M | 46.78M | -154.19M | 217K |
| Net Income | 316.88M | 376.28M | 281.59M | 202.12M | 402.71M | 129.08M |
| EPS Basic | 2.64 | 3.5 | 2.13 | 1.48 | 2.86 | 0.95 |
| EPS Diluted | 2.56 | 3.43 | 2.1 | 1.44 | 2.74 | 0.91 |
| Basic Shares Outstanding | 119.84M | 107.46M | 137.40M | 140.50M | 144.41M | 139.85M |
| Diluted Shares Outstanding | 119.84M | 107.46M | 137.40M | 140.50M | 144.41M | 139.85M |
| Ebit | 485M | 487.40M | 367.09M | 265.86M | 256.04M | 149.68M |
| Ebitda | 890.64M | 536.17M | 422.43M | 317.17M | 278.89M | 147.53M |
| Net Income Continuous Operations | 316.88M | 376.28M | 281.59M | 202.12M | 402.71M | 129.08M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
